Krystal Biotech (NASDAQ:KRYS) Shares Gap Down to $161.10

Krystal Biotech, Inc. (NASDAQ:KRYS) gapped down prior to trading on Monday . The stock had previously closed at $161.10, but opened at $145.50. Krystal Biotech shares last traded at $156.83, with a volume of 263,735 shares traded.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on KRYS shares. William Blair restated an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Guggenheim upped their price objective on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Krystal Biotech in a report on Monday. Citigroup raised their price objective on Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Krystal Biotech has an average rating of “Buy” and an average target price of $171.00.

Krystal Biotech Stock Down 2.6 %

The business has a fifty day moving average price of $169.04 and a 200-day moving average price of $133.40. The stock has a market capitalization of $4.47 billion, a P/E ratio of 1,939.24 and a beta of 0.91.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.82. The firm had revenue of $42.14 million for the quarter, compared to analysts’ expectations of $27.43 million. During the same quarter last year, the company posted ($1.25) EPS. On average, equities analysts expect that Krystal Biotech, Inc. will post 1.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CAO Kathryn Romano sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the completion of the sale, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at approximately $2,145,823.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,087 shares of company stock valued at $6,210,591. 14.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. increased its position in shares of Krystal Biotech by 111.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock worth $83,000 after acquiring an additional 379 shares during the period. Quest Partners LLC purchased a new stake in shares of Krystal Biotech in the 4th quarter worth $127,000. Pier 88 Investment Partners LLC bought a new position in shares of Krystal Biotech during the 4th quarter worth $145,000. Fox Run Management L.L.C. purchased a new position in shares of Krystal Biotech during the third quarter valued at $219,000. Finally, Capstone Investment Advisors LLC bought a new stake in shares of Krystal Biotech in the fourth quarter valued at about $303,000. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).